Figure 6From: Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy Combined treatment increases survival motor neuron (SMN) expression and motor neuron numbers in mice with late-onset spinal muscular atrophy (SMA). (A, C) Western blots showing SMN expression in the brain (A) and spinal cord (C) in mice with late-onset SMA that received L-ascorbic acid (L-AA) or combined (n = 4 in each group) treatment. β-Actin was used as an internal control. (B, D) Quantification of SMN protein expression in (A, C). The mean ± SEM was calculated. (E, G) Histological staining of lumbar spinal cord samples on postnatal days (PNDs) 30 (E) and 90 (G) for the wild-type (WT) mice and mice with late-onset SMA that had received different treatments. Scale bar: 100 μm (E and G, upper panel); 50 μm (E and G, lower panel). (F, H) Quantification of motor neuron numbers in the spinal cords obtained from (E) and (G) (n = 3, 40 sections for each group were quantified). The mean ± SEM was calculated. ***P < 0.001, Student's t test.Back to article page